Clinical and immunological characteristics for BK polyomavirus-associated nephropathy after kidney transplantation.


Journal

Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460

Informations de publication

Date de publication:
08 2023
Historique:
revised: 08 07 2023
received: 05 01 2023
accepted: 10 07 2023
medline: 1 9 2023
pubmed: 30 8 2023
entrez: 30 8 2023
Statut: ppublish

Résumé

BK polyomavirus (BKPyV)-associated nephropathy (BKPyVAN) can cause a significant risk of allograft impairment after kidney transplantation (KT). Intact BKPyV-specific immunity is associated with viral containment. This study investigated BKPyV-specific immunological factors among KT recipients. This prospective study in a single transplant center from January 2019 to August 2019 assessed associations between clinical and immunological characteristics, with a focus on BKPyV-cell-specific immunity and BKPyVAN, among KT recipients aged ≥15 years. The numbers of interferon-gamma (IFN-γ)-producing CD4 In total, 100 KT recipients were included (mean age ± SD, 42 ± 11 years); 35% of the recipients were female patients, and 70% had received induction immunosuppressive therapy. The 1-year cumulative incidence of high-level BKPyV DNAuria (possible BKPyVAN) and (presumptive BKPyVAN) was 18%. Among 40 patients with immunological factor data, pre-KT %NK cells (hazard ratio [HR], 1.258; 95% confidence interval [CI], 1.077-1.469; p = .004) and %VP1-specific NK cells (HR, 1.209; 95% CI, 1.055-1.386; p = .006) were factors independently associated with possible and presumptive BKPyVAN. KT recipients with possible and presumptive BKPyVAN were more likely to exhibit significant mean coefficients of %NK, %VP1-specific NK, and %NKT cells at 1 month after KT than before KT (all p < .05). Individuals with nonspecific and VP1-specific NK cells before KT and increasing numbers of these cells after KT may be at risk for high-level BKPyV DNAuria and presumptive BKPyVAN. Further studies are needed to determine the utility of BKPyV-specific innate immune surveillance in predicting the occurrence of BKPyVAN.

Identifiants

pubmed: 37647426
doi: 10.1002/iid3.956
pmc: PMC10461421
doi:

Substances chimiques

Immunosuppressive Agents 0
Interferon-gamma 82115-62-6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e956

Informations de copyright

© 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.

Références

Nephrol Dial Transplant. 2015 Feb;30(2):209-17
pubmed: 24574543
Am J Transplant. 2005 Sep;5(9):2213-21
pubmed: 16095500
BMC Infect Dis. 2019 Nov 19;19(1):974
pubmed: 31744480
J Am Soc Nephrol. 2018 Feb;29(2):680-693
pubmed: 29279304
Nat Immunol. 2018 Feb;19(2):99
pubmed: 29348503
Transplant Proc. 2018 Jan - Feb;50(1):130-136
pubmed: 29407295
J Virol. 2001 Jan;75(1):544-7
pubmed: 11119625
Infect Dis (Lond). 2019 Jul;51(7):479-484
pubmed: 31012777
Infect Dis Clin North Am. 2018 Sep;32(3):599-613
pubmed: 30146025
Clin Microbiol Rev. 2017 Apr;30(2):503-528
pubmed: 28298471
Clin Infect Dis. 2020 Dec 3;71(9):2375-2385
pubmed: 32076718
Int J Organ Transplant Med. 2012;3(3):115-8
pubmed: 25013634
Pediatr Transplant. 2010 Aug;14(5):589-95
pubmed: 20353405
Kidney Int. 2013 Aug;84(2):233-5
pubmed: 23903417
PLoS One. 2017 May 31;12(5):e0177339
pubmed: 28562595
J Infect Dis. 1988 Jul;158(1):176-81
pubmed: 2839580
Transpl Infect Dis. 2017 Dec;19(6):
pubmed: 28865164
Virology. 2006 Oct 25;354(2):252-60
pubmed: 16904154
Clin Dev Immunol. 2013;2013:256923
pubmed: 24000288
J Virol. 2000 May;74(9):4093-101
pubmed: 10756021
BMC Infect Dis. 2016 Jul 22;16:342
pubmed: 27448566
Am J Transplant. 2016 Jun;16(6):1697-706
pubmed: 26699950
Korean J Intern Med. 2020 Mar;35(2):438-448
pubmed: 29865778
Transplantation. 2019 Apr;103(4):832-838
pubmed: 30086091
Infect Immun. 2007 May;75(5):2171-80
pubmed: 17353286
Clin Transplant. 2019 Sep;33(9):e13528
pubmed: 30859620
Kidney Int. 2013 Aug;84(2):359-65
pubmed: 23486513
Am J Kidney Dis. 2009 Jul;54(1):131-42
pubmed: 19394729
Transplant Proc. 2018 May;50(4):1077-1079
pubmed: 29731069
Viral Immunol. 2016 Mar;29(2):74-82
pubmed: 26752693
Front Immunol. 2015 Jun 16;6:307
pubmed: 26136745

Auteurs

Tanaya Siripoon (T)

Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

Nopporn Apiwattanakul (N)

Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Pannawat Mongkolrattanakul (P)

Division of Nephrology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Chutatip Tongsook (C)

Division of Virology, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Nattawut Unwanatham (N)

Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Suradej Hongeng (S)

Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Surasak Kantachuvesiri (S)

Division of Nephrology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Ramathibodi Excellence Center for Organ Transplantation, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Jackrapong Bruminhent (J)

Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Ramathibodi Excellence Center for Organ Transplantation, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH